168267-11-6Relevant articles and documents
PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-)
-
Page/Page column 19, (2008/12/07)
The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifuoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl- piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.
Synthesis of carbon-14 labelled NK-1 receptor antagonists GR203040 and GR205171
Cable, Karl M.,Wells, Guy N.,Sutherland, Derek R.
, p. 29 - 45 (2007/10/03)
Syntheses of carbon-14 labelled versions of NK-1 receptor antagonists GR203040 and GR205171 are described. The carbon-14 atoms were introduced by palladium (0) catalysed cyanation of iodoaromatic substrates.